Brain Scientific (OTCQB: BRSF) a neurology-focused medical device company, presented updates on its proprietary brain diagnostics technology at AES2020, the virtual annual meeting of the American Epilepsy Society, the world’s largest scientific meeting focused on epilepsy and clinical neurophysiology. BRSF released the latest version of its disposable electroencephalogram (“EEG”) device in October 2020: the NeuroCap with velcro enhancements, which provide better adhesion, ensuring easy application by any medical professional.
NeuroCap may provide significant benefits to healthcare providers because it can be easily applied without special training. The demand for EEG testing has been growing, but specialized EEG technologists are needed to perform the traditional diagnostic procedure. With NeuroCap, any clinical staff, including nurses and medical assistants can apply EEG cap in five minutes or less to expedite the EEG testing.
EEG testing is essential in medical care for patients diagnosed with epilepsy. Although almost 4% of people in the United States are diagnosed with epilepsy, BRSF data indicate that only 254 of 6,210 hospitals are level 4 epilepsy centers, which are medical facilities providing the highest level of care to epilepsy patients and equipped with 24/7 EEG services. The potential of this easy-to-use, cost-effective device to disrupt the slow and cumbersome EEG device space is particularly valuable in the current environment, which has seen an increase in the demand for brain diagnostics as a result of COVID-19.
In addition, emerging research is showing that COVID-19 can cause neurological damage, necessitating brain diagnostic procedures, increasing demand for EEG. Any opportunity to replace inefficient and expensive brain diagnostics procedures with innovative solutions that require less time may ease this built-up pressure.
As an FDA-cleared, easy-to-use, rapid EEG device that can provide results in minutes, the NeuroCap can help bridge that widening gap in the neurological devices market. Committed to closing this gap, Brain Scientific is providing further enhancements of its NeuroCap, including the newest version with velcro adhesions for easier and faster diagnostics, potentially saving time necessary to complete the procedure for each patient. Brain Scientific is dedicated to making the once time-consuming diagnostic process easier for medical staff and more comfortable for patients with each improvement.
For more information, visit the company’s website at www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate…
For a long time, scientists have been working tirelessly to come up with vaccines against cancer. Significant progress is…
A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate…
Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected…
Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.…
Enormous resources are being channeled into studying different ways to support the immune system in its fight…